Positive allosteric modulators of mglur2

A compound according to Formula I

• wherein:
• Y is H, C1-6alkyl or C2-6alkenyl, said C1-6alkyl and C2-6alkenyl optionally substituted with 1 to 3 groups selected from:
• halo and C1-4alkoxy;
• R1 is selected from the group consisting of:
• (1) C2-8alkyl,
• (2) C2-8alkenyl,
• (3) C2-8alkynyl,
• (4) C3-6cycloalkyl-(CH2)p—, wherein p is 1, 2, 3 or 4,
• (5) benzyl,
• (6) biphenyl, and
• (7) 1-phenyl-1H-pyrazol-4-yl,
• wherein groups (1) to (7) above are optionally substituted with 1 to 3 R2 groups;
• each R2 is independently selected from the group consisting of:
• halo, OH, C1-4alkyl, C1-4alkoxy, CF3, —OCF3 and —CN;
• ring A is selected from aryl, heteroaryl and heterocycle, wherein said heterocycle is partially aromatic and the point of attachment is to the aromatic portion, and wherein said aryl, heteroaryl and heterocycle are optionally substituted with one or more R3 groups up to the maximum number of substitutable positions;
• each R3 is independently selected from the group consisting of:
• halo, —CN, —NO2, X, —C(R4)2—N(R)—X, —C(R4)2—N(R)C(O)—X, —C(R4)2—N(R)S(O)k—X, —C(R4)2—N(R)C(O)—O—X, —C(O)—X, —C(O)—O—X, —C(O)—N(R)—X, —S(O)k—X, —S(O)kN(R)—X, —N(R)—X, —O—X, —N(R)C(O)—X, —N(R)S(O)k—X, —N(R)C(O)—O—X, —N(R)C(O)N(R)—X and —N(R)SO2N(R)—X;
• each X is independently selected from the group consisting of:
• H, C1-8alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, aryl, heteroaryl, heterocycle, C3-6cycloalkyl-C(R4)2—, aryl-C(R4)2—, heteroaryl-C(R4)2— and heterocycle-C(R4)2—, wherein each member of the group excluding hydrogen is optionally substituted from one up to the maximum number of substitutable positions with one or more substituents independently selected from the group consisting of:
• CN, halo, R5, —O—R5, —N(R)—R5, —N(R)C(O)—R5, —N(R)S(O)2—R5, —N(R)—C(O)—O—R5, —C(O)—N(R)—R5, —C(O)—O—R5, —C(O)—R5, —C(O)—C(R4)2—R5, —C(O)—C(R4)2—S(O)2—R5, —C(R4)2—N(R)—R5, —SO2—N(R)—R5, —Si(CH3)2(R5), —C(R4)2—R5 and —SO2—R5;
• each k is independently 0, 1 or 2;
• each R is independently selected from the group consisting of:
• H and C1-4alkyl;
• each R4 is independently selected from the group consisting of:
• H, OH and C1-4alkyl;
• each R5 is independently selected from the group consisting of:
• H, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl, phenyl, heterocycle and heteroaryl, wherein each member of the group excluding hydrogen is optionally substituted with 1 to 3 substituents independently selected from:
• halogen, cyano, hydroxy and methyl;
• aryl at each occurrence is independently selected from the group consisting of:
• phenyl, naphthyl, anthryl and phenanthryl;
• heteroaryl at each occurrence independently means a 5- or 6-membered monocyclic aromatic or 9- or 10-membered bicyclic aromatic, wherein at least one atom in the aromatic is selected from N(R), O and S, the sulfur optionally oxidized to sulfone or sulfoxide, and the remaining atoms are selected from C, N(R), O and S, the sulfur optionally oxidized to sulfone or sulfoxide;
• heterocycle at each occurrence independently means a 4- to 7-membered monocyclic non-aromatic ring, an 8- to 11-membered bi-cyclic, including spiro-cyclic, non- or partially-aromatic ring or a 12- to 20-membered tri-cyclic, including spiro-cyclic portions, non- or partially-aromatic ring, each optionally substituted with 1 to 2 oxo groups, wherein at least one atom is selected from N(R), O and S, the sulfur optionally oxidized to sulfone or sulfoxide, and the remaining atoms are selected from C, N(R), O and S, the sulfur optionally oxidized to sulfone or sulfoxide;
• and pharmaceutically acceptable salts thereof.